Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
4.450
-0.080 (-1.77%)
At close: Jun 12, 2026, 4:00 PM EDT
4.470
+0.020 (0.45%)
After-hours: Jun 12, 2026, 6:18 PM EDT
Precigen Employees
Precigen had 160 employees as of December 31, 2025. The number of employees increased by 17 or 11.89% compared to the previous year.
Employees
160
Change (1Y)
17
Growth (1Y)
11.89%
Revenue / Employee
$197,469
Profits / Employee
-$2,396,363
Market Cap
1.59B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 160 | 17 | 11.89% | 160 | 0 |
| Dec 31, 2024 | 143 | -59 | -29.21% | 143 | 0 |
| Dec 31, 2023 | 202 | -7 | -3.35% | 202 | 0 |
| Dec 31, 2022 | 209 | -302 | -59.10% | 209 | 0 |
| Dec 31, 2021 | 511 | 34 | 7.13% | 456 | 55 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ardelyx | 489 |
| Maravai LifeSciences Holdings | 416 |
| UroGen Pharma | 298 |
| Maze Therapeutics | 141 |
| MapLight Therapeutics | 133 |
| MoonLake Immunotherapeutics | 130 |
| Septerna | 130 |
| Inhibrx Biosciences | 110 |
PGEN News
- 1 day ago - Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices - PRNewsWire
- 4 days ago - Precigen Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 12 days ago - Precigen presents long-term follow-up data from study of Papzimeos - TheFly
- 13 days ago - Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years - PRNewsWire
- 15 days ago - Precigen price target raised to $14 from $11 at H.C. Wainwright - TheFly
- 16 days ago - Precigen receives orphan drug exclusivity for papzimeos in the U.S. - TheFly
- 16 days ago - Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States - PRNewsWire
- 17 days ago - Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference - PRNewsWire